Sarepta Therapeutics Outlines 2026 Priorities on Strong Cash Position NRIX Q1 2026 Earnings NarrowerthanExpected Loss Shares Edge Up on Steady Pipeline Progress DieselIsobutanol Blending Mandate Likely Later This Year Says MoRTH Secretary